David R. Spigel
机构：Sarah Cannon · ORCID：0000-0003-3215-9465
发表论文 908 篇 · 总被引 80013 次 · h-index 98
代表论文
- Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial (2026 · Nature Medicine · 被引 5)
- Clinical Presentation of MTAP Deletions in Real-World Settings: Lessons for the Clinical Development of Novel Targeted Therapies (2025 · JCO Precision Oncology · 被引 4)
- Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up (2025 · Advances in Therapy · 被引 3)
- INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2025 · Clinical Cancer Research · 被引 2)
- A PHASE 3, OPEN-LABEL RANDOMIZED TRIAL TO COMPARE RINATABART SESUTECAN VERSUS INVESTIGATOR'S CHOICE OF CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER: RAINFOL™-02 (ENGOT-OV86/GOG-3107) (2025 · International Journal of Gynecological Cancer · 被引 1)
- Biomarker Testing Rates and Patterns in Patients With Metastatic Non–Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices (2026 · JCO Precision Oncology)